ReviewSeminars in immunology2007
Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.
Review in Seminars in immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.Immunity · 2016Review
- New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation.Nature reviews. Immunology · 2014Review
- Cyclin-dependent kinase 2 controls peripheral immune tolerance.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.Cell cycle (Georgetown, Tex.) · 2012Article
- Protein kinase C signaling and cell cycle regulation.Frontiers in immunology · 2012Article
- CD4+CD25+ T regulatory cells from FIV+ cats induce a unique anergic profile in CD8+ lymphocyte targets.Retrovirology · 2010Article
- Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.British journal of pharmacology · 2009Review
- Biological targets for isatin and its analogues: Implications for therapy.Biologics : targets & therapy · 2007Article
- The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.Clinical immunology (Orlando, Fla.)Article
- Biochemical signaling of PD-1 on T cells and its functional implications.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
A large body of research has established the importance of costimulatory signals and proliferation for the generation of productive T cell immune responses. While costimulation and cell cycle progression are each individually necessary for CD4+ effector T cell differentiation, it has become clear that neither of these processes alone is sufficient to avoid anergy. This review outlines the links between T cell differentiation, tolerance, and the cell cycle, and highlights recent work that has implicated cyclin-dependent kinases as important regulators and potential targets for modulation of T cell immunity and tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.